Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Keytruda
Keytruda
Checkmate Pharma Clinches $27M for More Studies in Skin Cancer
Xconomy
Fri, 06/16/17 - 09:28 am
Checkmate Pharmaceuticals
melanoma
Keytruda
Merck
Keytruda bonanza inspires a facelift and plans to invest more than $600M in translational research
Endpoints
Thu, 06/15/17 - 09:37 am
Keytruda
Merck
R&D
LifeArc
Merck pauses Keytruda trials, raising concerns about class
BioPharma Dive
Wed, 06/14/17 - 11:41 am
Merck
Keytruda
clinical trials
How Merck hopes to win in I/O combos: Q&A with Roy Baynes
BioPharma Dive
Wed, 06/14/17 - 11:39 am
Merck
immuno-oncology
Keytruda
Opdivo
Bristol-Myers Squibb
Merck halts enrollment on two PhIII Keytruda combo studies as outside monitors flag a worrying rate of deaths
Endpoints
Mon, 06/12/17 - 09:37 pm
Merck
Keytruda
clinical trials
Multiple Myeloma
Merck cautiously steps into the PD-(L)1/CTLA-4 checkpoint fray. But should it ‘go big or go home’ instead?
Endpoints
Fri, 06/9/17 - 11:13 am
Merck
anti-PD-L1
Keytruda
MK-1308
Bristol-Myers Squibb
Why Array BioPharma Inc. Sank 13.5% in May
Motley Fool
Wed, 06/7/17 - 10:08 am
Array Biopharma
Bristol-Myers Squibb
Merck
Opdivo
Keytruda
binimetinib
encorafenib
An Unprecedented FDA Approval Bodes Well for this Drug Stock
Motley Fool
Wed, 06/7/17 - 10:05 am
Merck
FDA
Keytruda
biomarkers
solid tumors
ASCO17: Merck touts Keytruda bladder benefit post Tecentriq failure
BioPharma Dive
Mon, 06/5/17 - 12:13 pm
Merck
Keytruda
bladder cancer
Tecentriq
ASCO 2017
Incyte keeps the ASCO spotlight focused on its closely-watched IDO1 drug epacadostat
Endpoints
Mon, 06/5/17 - 10:08 am
Incyte
ASCO 2017
epacadostat
non-small cell lung cancer
Keytruda
How Did Bristol Lose An Edge In Lung Cancer? It's No Mystery, Says New R&D Boss
Forbes
Sat, 06/3/17 - 09:28 am
Bristol-Myers Squibb
lung cancer
R&D
Opdivo
Merck
Keytruda
The immuno-oncology market prepares for the inevitable question: 'What's next?'
Medical Marketing and Media
Thu, 06/1/17 - 02:51 pm
immuno-oncology
Keytruda
Merck
Opdivo
Bristol-Myers Squibb
On ASCO’s Eve, Experts Fret Over Backlash to Cancer Combo Frenzy
Xconomy
Wed, 05/31/17 - 10:59 am
ASCO 2017
cancer
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
Here's How the FDA Just Helped Trump Deliver on a Big Promise
Motley Fool
Fri, 05/26/17 - 11:44 am
FDA
Donald Trump
Merck
Keytruda
Pioneering Merck makes another breakthrough with PD-1 star Keytruda, grabbing first OK for a cancer biomarker
Endpoints
Wed, 05/24/17 - 10:59 am
Merck
Keytruda
FDA
biomarkers
cancer
Merck’s checkpoint star Keytruda grabs another FDA OK, steering past wreckage of a Roche disaster
Endpoints
Fri, 05/19/17 - 10:12 am
Merck
Keytruda
FDA
Roche
Tecentriq
Incyte gets a boost from a series of positive data snapshots for its epacadostat/Keytruda combo
Endpoints
Thu, 05/18/17 - 12:08 am
Incyte
epacadostat
ASCO 2017
Merck
Keytruda
non-small cell lung cancer
AstraZeneca Shows That With Immune Cancer Drugs, No One Knows What's Next
Forbes
Fri, 05/12/17 - 11:44 am
AstraZeneca
oncology
Imfinzi
Opdivo
Keytruda
Has Merck Lucked Into A $10 Billion Drug?
Forbes
Thu, 05/11/17 - 11:20 am
Merck
Keytruda
bladder cancer
non-small cell lung cancer
OncoSec inks deal with Merck to study drug-device therapy for metastatic melanoma
Drug Delivery Business News
Thu, 05/11/17 - 11:16 am
OncoSec
Merck
drug-device combos
metastatic melanoma
ImmunoPulse IL-12
Keytruda
devices
Pages
« first
‹ previous
…
17
18
19
20
21
22
23
24
25
…
next ›
last »